Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F055 - Late-breaking Research: Procedural Dermatology

Saturday, February 17; 9:00 AM - 11:00 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Describe ground-breaking scientific developments in dermatologic research.
  • Evaluate and apply information from recent investigations to clinical practice.

Description

These forums will highlight the latest ground-breaking observations in clinical, therapeutics, surgical, pediatric, dermatopathologic and basic research. Researchers are invited to submit abstracts describing their most recent results and the top scoring studies will be invited to discuss their findings in a brief oral presentation during one of the themed Forums.

Disclosures

  • Abels, Christoph: no financial relationships exist with commercial interests.
  • Alam, Murad, MD: Allergan, Inc – C(Fees); Amway Corporation – C(H); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); Pulse Biosciences – C(Fees);
  • Eichenfield, Lawrence F., MD: Allergan, Inc – C(H), I(Fees); Anacor Pharmaceuticals, Inc. – C(H); Cutanea Life Sciences – C(H); Dr. Reddy – C(H); DS Laboratories – C(H); Elsevier Inc. – O(IP); Galderma Laboratories, L.P. – C(H), I(Fees); Genentech, Inc. – C(H); Kimberly Clark – I(Fees); LEO Pharma, US – C(H), I(Fees); Lilly ICOS LLC – C(H); Medimetriks Pharmaceuticals, Inc. – C(H); Novan – C(H), I(Fees); Otsuka Pharmaceutical Co., Ltd. – C(H); Pfizer Inc. – C(H); Ralexar Therapeutics, Inc – C(H); Sanofi/Regeneron – C(H), I(Fees); Tioga Pharmaceuticals, Inc. – C(H); TopMD – C(SO); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – I(Fees); Wiley-Blackwell – O(H);
  • Hebert, Adelaide A., MD: Allergan, Inc. – I(Grants/Research Funding); Amgen – I(Grants/Research Funding), SP(H); Anacor Pharmaceuticals, Inc. – A(H); Astellas Pharma US, Inc – I(Grants/Research Funding); Bayer – SP(H); Cassiopia – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Chugai Pharma – I(Grants/Research Funding); Cutanea Life Sciences – A(H), I(Grants/Research Funding); Department of DEFENSE – O(Grants/Research Funding); Dermavant Sciences – I(Grants/Research Funding); Dermira – A(H), I(Grants/Research Funding); Encore Dermatology, Inc. – A(H); Galderma Laboratories, L.P. – A(H), SP(H); GlaxoSmithKline – A(H), Data Safety Monitoring Board(H), I(Grants/Research Funding); Healthpoint – I(Grants/Research Funding); Intendis, Inc. – SP(H); Mayne Pharma Group – I(Grants/Research Funding); Medimetriks Pharmaceuticals, Inc. – I(Grants/Research Funding); Menarini Group – SP(H); Menlo Therapeutics – A(H); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); NIH – I(Grants/Research Funding); Novan – I(H); Novartis Pharmaceuticals Corp. – O(H); Onset Therapeutics – SP(H); Ortho Dermatologics – A(H); Pfizer Inc. – Speaker/Faculty Education(H); Pharmaderm – A(H); PPD Inc. – I(Grants/Research Funding); Prim-Med – SP(H); Promius Pharma, LLC – A(H); Promius Pharmaceuticals – A(H), I(Grants/Research Funding); Regeneron – Data Safety Monitoring Board(H); Roivant Sciences – A(H); Shionogi USA – A(IP); Sienna Biopharmaceuticals – I(Grants/Research Funding); Sinclair Pharma – SP(H); Stiefel a GSK company – A(H); TopMD – I(Grants/Research Funding); Valeant Pharmaceuticals International – A(H), SP(H); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding);
  • Kentley, Jonathan, MBBS: no financial relationships exist with commercial interests.
  • Kircik, Leon H., MD: 3M Pharmaceuticals – I(Grants/Research Funding), SP(H); Abbott Laboratories – SP(H); Ablynx – I(Grants/Research Funding); Acambis – I(Grants/Research Funding); Allergan, Inc – A(H), C(H), I(H), SP(H); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding), SP(H); Astellas Pharma US, Inc – I(Grants/Research Funding), SP(H); Asubio Pharmaceuticals, Inc. – I(Grants/Research Funding); Bayer Consumer Healthcare Pharmaceuticals – I(Grants/Research Funding); Biogen – A(H); Biolife – I(Grants/Research Funding); Biopelle, Inc. – I(Grants/Research Funding); Breckinridge Pharma – I(Grants/Research Funding); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); ColBar LifeScience Ltd. – A(H), C(H); CollaGenex Pharmaceuticals, Inc. – C(H), I(Grants/Research Funding), SP(H); Connetics Corporation – A(H), C(H), I(Grants/Research Funding); Coria Laboratories – I(Grants/Research Funding); Dermik Laboratories, a business of sanofi-aventis U.S. LLC – SP(H); Dow Pharmaceutical Sciences, Inc. – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Embil Pharmaceuticals, Co., Ltd – SP(H); EOS – A(H); Ferndale Laboratories, Inc. – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), C(H), I(Grants/Research Funding), SP(H); Genentech, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); GlaxoSmithKline – I(Grants/Research Funding); Healthpoint – I(Grants/Research Funding); Intendis, Inc. – A(H), C(H), I(Grants/Research Funding); Isdin – A(H); Johnson & Johnson Consumer Products Company – A(H), C(H), I(Grants/Research Funding), SH(ST), SP(H); Laboratory Skin Care, Inc. – C(H); Leo Pharma Inc – C(H), I(Grants/Research Funding), SP(H); Medical International Technologies – C(H); Medicis Pharmaceutical Corporation – I(Grants/Research Funding); Merck & Co., Inc – C(H); Merck Serono – SP(H); Merz Pharmaceuticals, LLC – C(H); NanoBio Corporation – A(H), I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Nucryst – I(Grants/Research Funding); Obagi Medical Products – I(Grants/Research Funding); Onset Dermatologics – I(Grants/Research Funding), SP(H); Othro Dermatologics – A(H), C(H), I(Grants/Research Funding), SP(H); Pfizer Inc. – I(Grants/Research Funding); Pharmaderm – I(Grants/Research Funding), SP(H); Promius Pharma, LLC – A(H), C(H), I(Grants/Research Funding); PuraCap Pharmaceutical – C(H); QLT Inc. – I(H); SkinMedica, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); Stiefel a GSK company – A(H), C(H), I(Grants/Research Funding), SP(H); Sun Pharmaceutical Industries Ltd. – A(H); TolerRx – I(Grants/Research Funding); Triax Pharmaceuticals, LLC – C(H), I(Grants/Research Funding), SP(H); Valeant Pharmaceuticals International – A(H), C(H), I(Grants/Research Funding), SP(H); Warner Chilcott – A(H), I(Grants/Research Funding), SP(H); Xenoport, Inc. – I(Grants/Research Funding); Zalicus – I(Grants/Research Funding);
  • Maisel, Amanda: no financial relationships exist with commercial interests.
  • Rzany, Berthold: Almirall – C(H); Croma-Pharma GmbH Austria – I(Fees); Evolus, Inc. – C(H); Merz Pharmaceuticals, LLC – C(H);
  • Smith, Stacy R., MD: AbbVie – I(Grants/Research Funding), SP(H); Aclaris Therapeutics Inc. – I(Grants/Research Funding); Aclaris Therapeutics, Inc. – C(Fees); Allergan, Inc. – I(Grants/Research Funding); AmperSand Biopharmaceutical, LLC – I(Grants/Research Funding); Aqua – C(Fees); Boehringer Ingelheim – I(Grants/Research Funding); Brickell Biotech, Inc. – I(Grants/Research Funding); Croma-Pharma GmbH Austria – I(Grants/Research Funding); Dermira – I(Grants/Research Funding); Dow Pharmaceutical Sciences, Inc. – I(Grants/Research Funding); Endo International plc – I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding); Glenmark Generics Inc. – I(Grants/Research Funding); Illumicare – I(Grants/Research Funding); Leo Pharma Inc – I(Grants/Research Funding); Lilly ICOS LLC – A(H), I(Grants/Research Funding), SP(H); Menlo Therapeutics – I(Grants/Research Funding); Novan – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H), I(Grants/Research Funding); Otsuka Pharmaceutical Co., Ltd. – Data Safety Monitoring Board(Fees); Pfizer Inc. – I(Grants/Research Funding); Regeneron – I(Grants/Research Funding); Revance Therapeutics, Inc. – I(Grants/Research Funding); Scarless Labs – C(Fees); SkinMedica, Inc. – I(Grants/Research Funding); Suneva Medical, Inc. – C(Fees), I(Grants/Research Funding); Taro Pharm – I(Grants/Research Funding); TEOXANE Laboratories – C(Fees);
  • Songco, Julie Anne Patricia: no financial relationships exist with commercial interests.
  • Tsao, Hensin, MD, PhD: Epiphany Dermatology – A(H); Massachusetts General Hospital – E(S); Relay Therapeutics – I(Grants/Research Funding);
  • Tsao, Sandy Sharon, MD: no financial relationships exist with commercial interests.
  • Win, Thet Su, MD: no financial relationships exist with commercial interests.
Schedule
Saturday, February 17
9:00 AM
Dr. Smith / A Multicenter, Randomized, Double-Blinded, Vehicle-controlled Study to Evaluate the Safety and Efficacy of 5%, 10% and 15% Topically Applied Sofpironium Bromide Gel in Subjects with Axillary Hyperhidr
9:12 AM
Kentley / The Burden of Cutaneous Disease in Solid Organ Transplant Recipients with Skin of Colour
9:24 AM
Dr. Kircik / Once-Daily Oral Sarecycline 1.5 mg/kg/day for Moderate to Severe Acne Vulgaris: Pooled Data From Two Phase 3 Pivotal Studies
9:36 AM
Dr. Abels / Glycopyrronium Bromide-containing Topical Formulations are Safe and Highly Effective in Patients with Primary Axillary Hyperhidrosis
9:48 AM
Win / Inflammatory Dermatoses Versus Immune Rejection in Clinical Face Transplants – The Role of Molecular Analysis
10:00 AM
Dr. Eichenfield / Serial Photographic Assessment of Effect of Oxymetazoline Cream 1.0% on Persistent Facial Erythema of Rosacea
10:12 AM
Rzany / A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe G
10:24 AM
Dr. Hebert / Evaluation of the Efficacy, Safety, and Tolerability of SB204 4% Once Daily in Subjects with Moderate to Severe Acne Vulgaris Treated Topically for Up to 52 Weeks
10:36 AM
Maisel / Treatment of Facial Flushing with Botulinum Toxin A injections: A Split-face, Double-blinded, Randomized Control Trial
10:48 AM
Songco / Narrowband-UVB (NB-UVB) Phototherapy as an Adjuvant to Clobetasol Propionate 0.05% Ointment in the Treatment of Alopecia Areata (AA) Among Adult Filipinos Aged 18-60 Seen in Makati Medical Center: A R
Event Details
  • Date
    Saturday, February 17
  • Time
    9:00 AM - 11:00 AM
  • Location
    Room 6D
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
Speakers
  • Adelaide A. Hebert, MD, FAAD
  • Amanda Maisel
  • Berthold Rzany
  • Christoph Abels
  • Jonathan Kentley, MBBS - Handout
  • Julie Anne Patricia Songco
  • Lawrence F. Eichenfield, MD, FAAD
  • Leon H. Kircik, MD, FAAD
  • Murad Alam, MD, FAAD
  • Sandy Sharon Tsao, MD, FAAD
  • Stacy R. Smith, MD, FAAD
  • Thet Su Win, MD